Beyond Platinum Resistance: Reconsidering Platinum Sensitivity as a Dynamic Phenotype in Ovarian Cancer
4 affiliations
- 1Cancer Research Program, Research Institute, McGill University Health Centre, Montreal, QC H4A 3J1, Canada
- 2Center for Molecular Medicine, MaineHealth Institute for Research, Scarborough, Maine, ME 04074, USA
- 3Department of Pathology, Faculty of Medicine and Health Sciences, McGill University, Montreal, QC H3A 2B4, Canada
- 4Gerald Bronfman Department of Oncology, Faculty of Medicine and Health Sciences, McGill University, Montreal, QC H4A 3T2, Canada
Abstract
Platinum-based chemotherapy remains a key treatment for epithelial ovarian cancer, but platinum resistance is a major cause of treatment failure and mortality. Traditionally, platinum resistance has been defined by the interval between the last platinum treatment and disease progression, with progression within six months generally classified as platinum-resistant. This six-month platinum-free interval has long provided a useful framework for treatment selection. However, growing preclinical and clinical evidence suggests that this interval should not be treated as a strict biological boundary. Platinum susceptibility can change as tumors evolve, with some tumors retaining residual sensitivity while others develop stable or potentially modifiable resistance mechanisms. These mechanisms include restoration of homologous recombination, altered DNA-damage tolerance, epigenetic regulation, changes in platinum transport and detoxification, adaptive survival signaling, and alterations in cell-death pathways. Some resistance mechanisms are relatively stable, whereas others may remain biologically plastic and potentially amenable to therapeutic modification. This distinction has important implications for platinum rechallenge. Responses to platinum reintroduction in selected patients previously classified as platinum-resistant indicate that the six-month interval does not fully capture the biology of platinum responsiveness. However, renewed clinical activity after rechallenge should not automatically be interpreted as biological resensitization. True resensitization requires evidence that a defined resistance mechanism has been modified and that this alteration increases platinum susceptibility. Preclinical studies have identified multiple strategies to modify platinum-resistance pathways, but clinical translation remains limited. This perspective therefore proposes that platinum resistance should be understood as a clinically defined phenotype encompassing biologically heterogeneous states, some of which may be stable and others potentially reversible. Recognizing this distinction has implications for biomarker development, treatment selection, trial design, and interpretation of platinum rechallenge. Prospective studies incorporating longitudinal tumor profiling and functional assessments of platinum susceptibility may ultimately identify patients in whom platinum activity can be therapeutically restored.
Related
- Beyond platinum sensitivity: immune-engaging therapies and multidimensional treatment stratification in relapsed small-cell lung cancer
- Multifaceted Impact of MicroRNA 493-5p on Genome-Stabilizing Pathways Induces Platinum and PARP Inhibitor Resistance in BRCA2-Mutated Carcinomas
- Targeting MAT2A-S-adenosylmethionine (SAM) Axis Attenuates DNA Damage Response and Cancer Stemness to Increase Platinum Sensitivity in Ovarian Cancer
- ACSF2 Functions as a regulatory switch for PARP inhibitor sensitivity in platinum-sensitive and homologous recombination-proficient high-grade serous ovarian cancer.
- Overcoming platinum resistance by the disulfiram metabolite CuET in novel preclinical models of human carcinomas
BibTeX
@article{goyeneche2026beyond,
title = {{Beyond Platinum Resistance: Reconsidering Platinum Sensitivity as a Dynamic Phenotype in Ovarian Cancer}},
author = {Alicia A. Goyeneche and Adriana E. Rosato and Roberto R. Rosato and Carlos M. Telleria},
journal = {Cancers},
year = {2026},
month = oct,
doi = {10.3390/cancers18203295},
url = {https://www.mdpi.com/2072-6694/18/20/3295},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Beyond Platinum Resistance: Reconsidering Platinum Sensitivity as a Dynamic Phenotype in Ovarian Cancer
AU - Alicia A. Goyeneche
AU - Adriana E. Rosato
AU - Roberto R. Rosato
AU - Carlos M. Telleria
PY - 2026
DA - 2026/10/01
JO - Cancers
DO - 10.3390/cancers18203295
UR - https://www.mdpi.com/2072-6694/18/20/3295
AB - Platinum-based chemotherapy remains a key treatment for epithelial ovarian cancer, but platinum resistance is a major cause of treatment failure and mortality. Traditionally, platinum resistance has been defined by the interval between the last platinum treatment and disease progression, with progression within six months generally classified as platinum-resistant. This six-month platinum-free interval has long provided a useful framework for treatment selection. However, growing preclinical and clinical evidence suggests that this interval should not be treated as a strict biological boundary. Platinum susceptibility can change as tumors evolve, with some tumors retaining residual sensitivity while others develop stable or potentially modifiable resistance mechanisms. These mechanisms include restoration of homologous recombination, altered DNA-damage tolerance, epigenetic regulation, changes in platinum transport and detoxification, adaptive survival signaling, and alterations in cell-death pathways. Some resistance mechanisms are relatively stable, whereas others may remain biologically plastic and potentially amenable to therapeutic modification. This distinction has important implications for platinum rechallenge. Responses to platinum reintroduction in selected patients previously classified as platinum-resistant indicate that the six-month interval does not fully capture the biology of platinum responsiveness. However, renewed clinical activity after rechallenge should not automatically be interpreted as biological resensitization. True resensitization requires evidence that a defined resistance mechanism has been modified and that this alteration increases platinum susceptibility. Preclinical studies have identified multiple strategies to modify platinum-resistance pathways, but clinical translation remains limited. This perspective therefore proposes that platinum resistance should be understood as a clinically defined phenotype encompassing biologically heterogeneous states, some of which may be stable and others potentially reversible. Recognizing this distinction has implications for biomarker development, treatment selection, trial design, and interpretation of platinum rechallenge. Prospective studies incorporating longitudinal tumor profiling and functional assessments of platinum susceptibility may ultimately identify patients in whom platinum activity can be therapeutically restored.
SN - 2072-6694
ER -